Pharmaceutical Purified Water and WFI Systems: RO, EDI and Distillation Design
Pharmaceutical water is a raw material with a specification, not a utility. Purified water and water for injection must satisfy pharmacopoeial requirements for conductivity, total organic carbon and microbial bioburden on every day of operation, and the design emphasis therefore falls on sanitisation and control rather than on treatment efficiency alone. A system that produces compliant water on commissioning day but develops a biofilm in month three has failed.
Three pharmacopoeial grades dominate: purified water, highly purified water and water for injection. Purified water is the standard grade for non-sterile preparation and cleaning. Highly purified water applies a stricter bacterial endotoxin limit and is recognised in the European Pharmacopoeia. Water for injection adds a bacterial endotoxin limit of 0.25 endotoxin units per millilitre and must be produced by distillation or by a validated equivalent process. Where the upstream feed requires treatment to make it suitable for these systems, the techniques overlap with general sand filter and activated carbon pretreatment, but the validation and documentation demands are far greater.
Water Quality Requirements
Purified Water
Conductivity below 1.3 microsiemens per centimetre at 25 degrees Celsius, or within the pharmacopoeial stage 3 table
Total organic carbon below 0.50 mg/L
Microbial bioburden below 100 colony forming units per millilitre with an action limit typically set at 50
Nitrates below 0.2 parts per million where specified
Water for Injection
All purified water requirements, plus bacterial endotoxins below 0.25 EU/mL
Produced by distillation in a validated still, or by a process validated as equivalent
Held and distributed above 80 degrees Celsius, or circulated continuously with rigorous sanitisation
Pretreatment Train
Pharmaceutical water systems almost always begin with a well-defined pretreatment train, because membranes and stills downstream require stable, low-fouling feed.
Multimedia filtration: removes suspended solids to protect downstream carbon and softener beds
Activated carbon: removes chlorine and chloramine, which would otherwise destroy reverse osmosis membranes, and adsorbs organics; requires periodic hot water or steam sanitisation to control microbial growth
Water softening: removes hardness to prevent scaling of reverse osmosis membranes; the softening chemistry is the same as that used in boiler feedwater softening and demineralisation
Antiscalant dosing: provides a secondary barrier against carbonate and sulphate scaling where softening is incomplete
Ultraviolet irradiation at 185 nanometres: optional destruction of residual chlorine and organics ahead of the reverse osmosis stage
Reverse Osmosis and Electrodeionisation
The combination of reverse osmosis followed by electrodeionisation is the dominant technology for purified water generation, having largely displaced the two-pass reverse osmosis and mixed bed deionisation arrangements of earlier generations.
Reverse Osmosis Stage
A single-pass reverse osmosis stage with a polyamide thin film composite membrane removes 95 to 99 percent of dissolved ions and more than 99 percent of bacteria, endotoxins and organic molecules above 200 daltons. Design parameters include a recovery of 65 to 75 percent, flux of 15 to 22 litres per square metre per hour, and a concentrate stream with sufficient cross-flow velocity to control concentration polarisation. Two-pass configurations are used where the feed is high in dissolved solids or where the first pass alone cannot reliably achieve pharmacopoeial conductivity.
Electrodeionisation Stage
Electrodeionisation uses ion exchange membranes and resin in a direct current field to remove residual ions continuously, without the chemical regeneration required by conventional deionisation. The resin is regenerated in situ by the electric current, splitting water into hydrogen and hydroxyl ions that continuously regenerate the resin bed. This eliminates the caustic and acid regeneration chemicals that are the primary contamination risk in mixed bed systems.
Electrodeionisation requires feed water with conductivity below about 40 microsiemens per centimetre, which is why it is always paired with reverse osmosis upstream. Typical product water reaches a resistivity of 15 to 18 megohm-centimetres, exceeding pharmacopoeial requirements with margin, and the process is continuous and inherently sanitisation-friendly because it operates without chemical regeneration.
The operating constraints that protect reverse osmosis membranes in pharmaceutical service are the same fundamentals that govern membrane fouling prevention and cleaning protocols: limiting flux, maintaining cross-flow, and cleaning on the basis of normalised permeability rather than elapsed time.
Water for Injection Generation
Distillation remains the reference method for water for injection because it is robust, easy to validate, and provides a phase change that reliably removes endotoxins and micro-organisms.
Still Configurations
Multi-effect still: uses vapour from one effect to heat the next, achieving 1.2 to 1.5 kilograms of distillate per kilogram of steam with three effects; the most common configuration
Vapour compression still: recovers latent heat through mechanical compression and achieves the lowest energy consumption per litre of distillate, at higher capital cost and compressor maintenance burden
Pure steam generation: supplies clean steam for both the still and for autoclaves, clean-in-place and humidification, allowing shared infrastructure
Still design must ensure that entrainment of feed water droplets into the vapour is prevented, since endotoxins are not volatile and are carried only by liquid droplets. Cyclone separators and sufficient vapour disengagement height are the standard defences, together with a consistent boiling regime that avoids foaming.
Distribution and Storage
Water for injection is stored and circulated at above 80 degrees Celsius to suppress microbial growth, with a continuous loop returning to the storage tank and no dead legs anywhere in the system. Loop velocities are maintained above 1.5 metres per second to keep surfaces scoured, and all connections are made with zero dead leg diaphragm valves. Where a plant operates a combined loop, the purified water side is often circulated at 20 to 25 degrees Celsius with periodic thermal sanitisation or ozonation, while the water for injection side is continuously hot.
Sanitisation and Microbial Control
Microbial control is the principal operational challenge in pharmaceutical water systems, and pharmacopoeial compliance depends on it.
Thermal sanitisation: circulating water above 80 degrees Celsius; the most reliable method, applicable to distribution loops and storage vessels
Ozonation: applied to purified water loops at 0.1 to 0.2 mg/L residual, with ultraviolet destruction of residual ozone before use; effective against biofilm but requires careful monitoring
Hot water sanitisation of reverse osmosis: membranes rated to 80 to 90 degrees Celsius permit periodic thermal sanitisation as in high-temperature membrane cleaning regimes
Periodic sampling: routine sampling at every use point on a rotating schedule, with trend analysis rather than pass-fail assessment alone
Biofilm is the recurring failure mode. Once established in a loop, it sheds micro-organisms continuously and resists chemical sanitisation. The design defence is the elimination of dead legs, crevices, rough weld surfaces and low-velocity sections, combined with a sanitisation schedule that prevents biofilm establishment in the first place.
Validation Requirements
A pharmaceutical water system must be validated in three phases.
Phase 1, commissioning: two to four weeks of intensive daily sampling at every use point to demonstrate consistent quality under defined operating conditions
Phase 2, provisional: two to four weeks of daily sampling to confirm that the system operates reproducibly with standard operating procedures in place
Phase 3, ongoing: one year of monitoring with reduced frequency, on the basis of which the routine monitoring programme is defined
Documentation must cover design qualification, installation qualification, operational qualification and performance qualification, together with change control for any alteration to the system. This validation burden is the principal reason why pharmaceutical water systems are specified with more instrumentation and more conservative design margins than other industrial water plants, including the process design of pharmaceutical wastewater treatment and zero liquid discharge systems on the discharge side of the same facility.
Conclusion
Pharmaceutical purified water and water for injection systems are engineering solutions to a regulatory problem. Reverse osmosis followed by electrodeionisation provides purified water with exceptional reliability and no chemical regeneration risk, while distillation remains the reference method for water for injection. The determinant of long-term success is not the treatment technology but the control of biofilm through loop design, velocity and sanitisation discipline, supported by the validation documentation that the regulatory framework requires.
Frequently Asked Questions
Can reverse osmosis alone produce water for injection?
Regulatory pharmacopoeias require water for injection to be produced by distillation or by a process proven equivalent. Reverse osmosis with electrodeionisation is accepted for purified water and, where local regulation permits, for highly purified water, but water for injection normally requires distillation. Some jurisdictions accept validated reverse osmosis with ultrafiltration for non-sterile applications only.
Why is electrodeionisation preferred over mixed bed deionisation?
Electrodeionisation regenerates continuously in situ using electric current, eliminating the acid and caustic regeneration chemicals that represent a contamination risk and a documentation burden in mixed bed systems. It also operates continuously rather than in batch cycles, which improves water quality consistency. Its limitation is that it requires reverse osmosis permeate as feed, typically below 40 microsiemens per centimetre, which is why the two processes are always paired.
What circulation velocity should a pharmaceutical water loop maintain?
Above 1.5 metres per second, and preferably 2 to 3 metres per second, to maintain turbulent flow that scours the pipe wall and prevents biofilm attachment. Lower velocities create laminar boundary layers where micro-organisms can establish colonies, and are a frequent finding in audits of older systems. The same velocity principle protects surfaces in membrane systems requiring biofilm control.
